Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly ...

The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first ...

Low doses of glucocorticoids added to immunosuppression yield no significant benefit for skin fibrosis in early diffuse ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Baxdrostat is a drug that reduces aldosterone levels in the body to treat high blood pressure and other conditions. It's an ...

Overactivation of the system contributes to inflammation and fibrosis in the kidneys and ... in which Kerendia reduced the risk of kidney disease progression or renal death by 18% when added ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

And if we use senolytics, we see that the inflammation goes away and the regenerative capacity of the surrounding tissue is restored — well, at least if you’re a mouse.” Based on dozens of preclinical ...

Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...

Vertex has built its business on genetic medicines for cystic fibrosis, which generated ... across multiple indications. In the kidney disease category, its pipeline includes inaxapalin (VX ...

United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...